Minimal Disease Activity among Active Psoriatic Arthritis Patients Treated with Secukinumab: 2-year Results from the FUTURE 2 Study.
Document Type
Article
Publication Date
2-6-2018
Publication Title
Arthritis Care Res (Hoboken)
Keywords
Anti-TNF; Disease Activity; Inflammation; Psoriatic Arthritis; Remission; Spondyloarthritis
Abstract
OBJECTIVE: To evaluate minimal disease activity (MDA) among psoriatic arthritis (PsA) patients receiving secukinumab through 2 years in the FUTURE 2 study (NCT01752634).
METHODS: Patients with active PsA were randomized to receive subcutaneous secukinumab 300, 150, or 75 mg or placebo. MDA was assessed in the overall population (anti-tumor necrosis factor [TNF]-naïve and inadequate responders [anti-TNF-IR]) and in patients stratified by prior anti-TNF exposure and by time since diagnosis at Weeks 16, 24, 52, and 104. Function, patient-reported outcomes (PROs) including health-related quality of life (QoL), and work productivity were assessed in MDA responders versus non-responders.
RESULTS: Overall, 28% (27/98) and 23% (23/100) of patients achieved MDA at Week 16 with secukinumab 300 and 150 mg, respectively, versus 10% (9/94) with placebo. In the anti-TNF-naïve cohort, a higher proportion of patients achieved MDA at Week 16 with secukinumab 300 and 150 mg (34% and 32%, respectively) versus placebo (13%). The corresponding value in the anti-TNF-IR cohort was 15% and 8% with secukinumab 300 and 150 mg, respectively, versus placebo (3%). At Week 16, 27.1% (16/59) of MDA responders achieved a very low disease activity (VLDA) response, with the percentage being numerically greater with secukinumab 300 and 150 mg (30% [8/27] and 26% [6/23], respectively) versus placebo (22% [2/9]). The MDA and VLDA responses with secukinumab 300 and 150 mg were sustained through 2 years. MDA responders showed greater improvements in QoL outcomes compared to non-responders through 2 years.
CONCLUSION: A greater proportion of patients achieved MDA with secukinumab versus placebo at Week 16, with response rates sustained through 2 years. MDA was associated with improved PROs, including QoL, through 2 years. This article is protected by copyright. All rights reserved.
Clinical Institute
Orthopedics & Sports Medicine
Department
Rheumatology
Recommended Citation
Coates, Laura C; Mease, Philip; Gossec, Laure; Kirkham, Bruce; Sherif, Bintu; Gaillez, Corine; Mpofu, Shephard; Jugl, Steffen M; Karyekar, Chetan; and Gandhi, Kunal K, "Minimal Disease Activity among Active Psoriatic Arthritis Patients Treated with Secukinumab: 2-year Results from the FUTURE 2 Study." (2018). Articles, Abstracts, and Reports. 39.
https://digitalcommons.providence.org/publications/39
